Global Proteomics Market

The protein labeling market consists of sales of protein labeling products and related services by entities (organizations, sole traders and partnerships) that produce protein labeling products to diagnose various diseases. Protein labeling refers to the use of appropriate molecular labels to detect or purify proteins and their binding partners in tissues, cells, and biochemical assays. The protein labeling market covered in this report is segmented by product into reagents, protein, enzymes, probes/ tags, monoclonal antibodies; by labeling method into in-vitro labeling, in-vivo labeling; by application into cell based-assay, fluorescence microscopy, immunological techniques, mass spectrometry, protein microassay. The global protein labeling market is expected to grow from $1.6 billion in 2020 to $1.77 billion in 2021 at a compound annual growth rate (CAGR) of 10.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The protein labeling market is expected to reach $2.79 billion in 2025 at a CAGR of 12%. Increased spending on the R&D of proteomics and genomics is driving the growth of the protein labeling reagents market. Proteomics is the study of the overall protein content of a cell, tissue, or organism. Protein labeling methods before separation and analysis is essential during proteomic profiling approaches. For instance, the National Institutes of Health (NIH) of the United States, funded $37 billion for biomedical research. This funding is for life sciences research that supports study at a molecular level for the understanding of fundamental processes by which diseases develop identification of biomarkers that signal the presence of disease, or identification of gene/protein responsible for the disease. The Novo Nordisk Foundation granted a grant of up to $1.5 million to the University of Copenhagen to establish a mass spectrometry facility, which marks a new and exciting step in protein research. Therefore, the increased spending on research and development of proteomics and genomics is driving the market. Drawbacks related to protein labeling techniques are expected to hinder the market. Label-free techniques are preferred over labeled techniques because of the drawbacks associated with them, such as wet-lab complexity and flexibility. While label-free samples can be measured without much preparation, wet lab pre-treatment is required for all labeling techniques. Samples must be labeled with metabolic (e.g. SILAC) or chemical (e.g. iTRAQ or TMT) reagents and the different conditions has to be combined. Therefore, label-free techniques are less prone to wet lab errors than labeling techniques. Label-free approaches have the advantage of being highly adaptable even after the study has begun. New samples can be included at any time, but labeled approaches require the same number (n) of each condition. New samples may not be included in the study if they cannot be physically mixed and measured together with the control. Labeled techniques such as the "Super-SILAC" approach reduce this problem but must also be carefully planned. These disadvantages are making label-free techniques preferable. Therefore, drawbacks associated with protein labeling techniques are expected to hinder the market. Companies in the protein labeling market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships, in or out-licensing deals, this trend has been increasing over recent years. For instance, in 2018 recombinant protein manufacturer enGenes Biotech GmbH (enGenes) announced a collaboration with ACIB GmbH for protein labeling. In January 2020, Abcam, a UK-based protein research tools producer and seller, announced its decision to acquire Expedeon's Proteomics and Immunology business, which includes Innova and TGR Biosciences. Expedeon technology supports a diverse set of labels, including enzymes, metals, oligos, and fluorescent proteins. Abcam will combine the newly acquired capture and conjugation technologies with its extensive antibody and protein expertise to expand and enhance its portfolio of off-the-shelf, and custom reagents and tools. Expedeon is a Germany-based manufacturer of protein discovery and analysis products used for protein and drug research. Major players in the protein labeling market are Thermo Fisher Scientific Inc, Merck KGaA, PerkinElmer, Inc., General Electric Company, F. Hoffmann-La Roche AG, AGILENT TECHNOLOGIES INC., BIO-RAD LABORATORIES, Kirkegaard & Perry Laboratories, LI-COR Inc., and Kaneka Corporation. The regions covered in the protein labeling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the protein labeling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global protein labeling market is segmented - 1) By Product: Reagents, Protein, Enzymes, Probes/ Tags, Monoclonal Antibodies 2) By Labeling Method: In-vitro Labeling, In-vivo Labeling 3) By Application: Cell Based-Assay, Fluorescence Microscopy, Immunological Techniques, Mass Spectrometry, Protein Micro Assay

Pharmaceuticals Market Definition

The pharmaceuticals market consists of sales of pharmaceuticals and related services by entities (organizations, sole traders and partnerships) that produce pharmaceuticals used in treating diseases. This industry includes establishments that produce biologics and pharmaceutical drugs. The pharmaceutical industry develops drugs to diagnose, cure, treat or prevent diseases, infections, and injuries. Pharmaceuticals are subjected to various laws and regulations that deal with patenting, testing, safety, efficacy and marketing. Pharmaceutical drug manufacturers produce pharmaceutical drugs made from active pharmaceutical ingredients (API) and excipients.

The protein expression market consists of sales of protein expression vectors, competent cells, reagents, equipment and related services. Protein expression is a process in which proteins are synthesized, modified, regulated and controlled in living organisms according to the host cell. Protein expression included yeast expression, insect expression, and bacterial expression, algal expression and mammalian cell expression. The protein expression market covered in this report is segmented by protein expression into yeast expression, mammalian expression, algae expression, insect expression, bacterial expression, cell-free expression. The protein expression market is also segmented by end use into pharmaceutical and biotechnological companies, academic research, contract research organizations; by product into reagents, competent cells, expression vectors, services, instruments; by application into therapeutic, industrial, research. The global protein expression market is expected to grow from $2.01 billion in 2020 to $2.13 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The protein expression market is expected to reach $3.03 billion in 2025 at a CAGR of 9.2%. Increase in demand for biologics to counter various genetic disorders and chronic diseases is one the major factors driving the research and sales of protein expression market. Biologics is a medicine produced from living organisms or contains components of living organisms such as protein, tissue, genes, allergens, cells, blood components, blood, and vaccines. The increasing use of biologics (therapeutic protein and others) to cure chronic diseases such as cancer, cardiovascular conditions and genetic disorders, is increasing the demand for protein expression devices and equipment. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. Hence the rising demand for biologics is driving the protein expression market. For instance, according to an article published by Chemistry World, analysts expect the biologics market to hold a market share of more than a quarter of the entire pharmaceutical market by 2020. The global biologics market is expected to grow at 9.9% during 2018-2024. Government regulations related to protein therapeutics and production of biologics may hinder the protein expression market growth. Government regulations on biologics to undergo rigorous preclinical and clinical trials prior to regulatory approval, and time consuming process for approval of biologics with regards to health and the safety of any individual are restraining the market growth. Marketing and distribution of biologics including insulin, hormones, therapeutic antibodies, and vaccines depends upon the successful completion of clinical trials, which is a long, expensive, and uncertain process. According to FDA, for an approval of new biologic, Under the regulations (21 CFR 314.81(b)(2)(vii) and 601.70, a clinical trial approval usually takes 10- 12 months where firms are required to submit a report annually on the status of clinical safety, clinical efficiency, clinical pharmacology, and nonclinical toxicology study. Companies in the industry are increasingly adopting Microfluidics technology to enhance protein expression tests in order to reduce the time, cost, labor, and increase the accuracy and performance. The microfluidics technology effectively analyzes biological samples than the traditional (macroscale) instruments. Microfluidics technology is used to measure the expression of proteins on cells and optimizes the output to generate results regarding protein expression. Therapeutics-on-a-chip (TOC) uses microfluidic platform and is able to synthesize proteins in a point of care setting to reduce cost associated with storage and transportation of therapeutic proteins. For instance, companies such as MissionBio, NanoCellect Biomedical, RainDance Technologies and Sphere fluidics have implemented this technology in protein expression test. The Protein Expression market in the U.S. is governed by Food and Drug Administration (FDA) that lays down a series of guidelines for the manufacturers and retailers of this industry. Within FDA, Center for Drug Evaluation and research (CDER) regulates biological products under FDA 101 which includes gene therapy products and vaccines. These regulations ensure quality, safety and efficacy of biological therapeutics products, and speed up innovations that make these products safer, and effective. The US’s FDA announced a fast-track initiative to review its drugs and biologics policy to speed the availability of therapies to patients with serious conditions, orphan drugs for rare disease, while preserving the safety and efficacy standards. FDA also removed a rule (Section 610.21 of the FDA code) which specified minimal potency limits for certain antibodies and antigens. The European Medicines Agency has also introduced policies which include a provision to waive the scientific advice fee, which encourage more academic groups and small companies to propose candidates for biologics. Major players in the protein expression market are Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., New England Biolabs and Promega Corporation. The regions covered in the protein expression market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the protein expression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global protein expression market is segmented - 1) By Protein Expression: Yeast Expression, Mammalian Expression, Algae Expression, Insect Expression, Bacterial Expression, Cell-free Expression 2) By End Use: Pharmaceutical And Biotechnological Companies, Academic Research, Contract Research Organizations 3) By Product: Reagents, Competent Cells, Expression Vectors, Services, Instruments 4) By Application: Therapeutic, Industrial, Research

The specialty enzymes market consists of sales of specialty enzymes which are proteins acting as biocatalysts to accelerate the rate of reactions. The revenue generated by the market involves the sales of specialty enzymes that include carbohydrases, proteases, lipases, among others in liquid or dry form, which are produced either from microorganisms, plants or animals. Specialty enzymes are primarily used in pharmaceutical, diagnostics, animal nutrition, food & beverage, research, and biotechnology. The specialty enzymes market covered in this report is segmented by type into carbohydrases, proteases, lipases, polymerases & nucleases, oxidase & hydratases, others. The specialty enzymes market is also segmented by source into microorganisms, animals, plants and by application into pharmaceutical, diagnostics, research & biotechnology, food & beverage, animal nutrition, others. The global specialty enzymes market is expected to grow from $4.28 billion in 2020 to $4.41 billion in 2021 at a compound annual growth rate (CAGR) of 3%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The specialty enzymes market is expected to reach $6.1 billion in 2025 at a CAGR of 8%. Growing investment in biotechnology research & development is expected to boost market growth during the forecast period. Specialty enzymes are widely used in biotech research and development, particularly in molecular biology. The increasing investment and an increase in the number of companies conducting biotechnology research & development will in turn increase the number of biotech researches. In 2018, the annual investment in UK biotechnology research & development was £2.2 billion which was up from the previous year (£1.2 billion) and there is a significant increase in the number of active companies involved in biotech research & development, which reached to 3,456 companies in 2018. There were 127 newer companies incorporated in just the first two months of 2019, which represents 3 new companies each new working day. Thus, the growing number of biotech research companies following increasing investments in biotech R&D is expected to boost the specialty enzymes market. Ethical and societal issues are factors that will slow down the market growth during the forecast period. The clashing public opinions on these issues will determine the acceptability of new industrial biotechnology products. In 2019, a published article stated that there are five societal and ethical themes concerning industrial biotechnology namely sustainability, naturalness, risk management, innovation trajectories and economic justice. Many critics state the factor affecting economic justice is that the applications of industrial biotechnology lead to the concentration of knowledge and power in the hands of a few companies. Thus, societal and ethical issues are expected to impact market growth. Technological advancements show opportunities for the production of enzyme products in a more efficient way. Challenges such as complexity in maintaining pH, operational high temperature of specialty enzymes and significant cost of maintenance of specialty enzyme products paves way for technological advancements. In 2019, an article published in Plant Biotechnology Journal stated the commercial launch of leaf pectinase powder developed using a new platform technology namely leaf-production platform. The leaf pectinase powder produced using leaf-production platform showed promising results like functionality in broad pH/temperature ranges as crude leaf extracts, leaf pectinase powder was stored up to 16 months at ambient temperature without loss of enzyme activity, unlike commercial enzyme products. This leaf-production platform is a novel technology for enzyme production with the elimination of fermentation, purification, concentration, formulation and cold chain processes. In 2018, BRAIN AG, a Germany-based industrial biotechnology company that identifies and develops innovative solutions and products for use in chemistry, cosmetics and food industries, acquired a majority stake in Biocatalysts Ltd for an undisclosed amount. The acquisition will strengthen BRAIN’s BioIndustrial segment and widens commercial opportunities with Biocatalyst's portfolio and technology including access to BRAIN’s unique BioArchive and Biocatalyst’s MetXtra metagenomic library. Biocatalysts Ltd. is a UK-based manufacturer of specialty enzymes that focuses on the use of technology to develop novel specialty enzymes in a cost-effective manner. Major players in the specialty enzymes market are BASF SE, Novozymes A/S, Roche Holding AG, Codexis Inc., Specialty Enzymes & Probiotics, Advanced Enzyme Technologies Ltd., BBI Solutions, E. I. du Pont de Nemours and Company, Sanofi, and Amano Enzyme Inc. The regions covered in the specialty enzymes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the specialty enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global specialty enzymes market is segmented - 1) By Type: Carbohydrases, Proteases, Lipases, Polymerases & Nucleases, Oxidase & Hydratases, Others 2) By Source: Microorganisms, Animals, Plants 3) By Application: Pharmaceutical, Diagnostics, Research & Biotechnology, Food & Beverage, Animal Nutrition, Others

The biosimilar interleukins market consists of sales of interleukin biosimilars generated by the establishments that manufacture interleukin biosimilars that are used to treat various autoimmune diseases. Interleukin is a substance derived from white blood cells that enhances infection activity and is used to fight certain types of cancer. The biosimilar interleukins market covered in this report is segmented by type into IL-17, IL-23, IL-1, IL-5, IL-6, others. It is also segmented by application into psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (IBD), others and by distribution channel into hospital pharmacies, online pharmacies, retail pharmacies, clinics, research institutes. The global biosimilar interleukins market is expected to grow from $1.03 billion in 2020 to $1.33 billion in 2021 at a compound annual growth rate (CAGR) of 29.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar interleukins market is expected to reach $4.94 billion in 2025 at a CAGR of 39%. The increasing prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is expected to boost the growth of the interleukin biosimilars market in the forecast period. Autoimmune disorders are conditions in which the immune cells cannot distinguish healthy cells from potentially dangerous antibodies. Biologic drugs such as anti-interleukin antibodies have shown significant clinical benefit in regulating the cells, and in directing proliferation, activation, and migration of the cells. According to the British Society for Immunology report 2018, many autoimmune disorders showed a year-on-year increase in incidence at rates between 3% and 9%. In the US, there were 7.4 million people affected with psoriasis in 2017 and this number is ever increasing. Therefore, the increasing prevalence of autoimmune diseases is increasing the demand for the biosimilar interleukins market and is expected to drive the growth of the market. The regulatory framework around the approval of interleukin biosimilars hampers the growth of the market. Biosimilars are manufactured with changes in the manufacturing process impacting the physicochemical and functional properties of a biologic drug and it is impractical to create an exact copy of the biologic drug. This compels the manufacturers to demonstrate biosimilarity between interleukin biosimilar and the biologic drug to prove that there are no clinically meaningful differences. This calls for extensive comparative analytical, nonclinical, and clinical assessments to get approval from the medical authorities, thereby, increasing the cost of the approval process and restraining the growth of the market. In January 2020, Sanofi, a France-based pharmaceutical company, acquired Synthorx, Inc. for $2.5 billion. This acquisition enhances Sanofi’s position as an emerging leader in the area of oncology and immunology. Synthorx, Inc. is a US-based biotechnology company focused on developing interleukins for people suffering from cancer and autoimmune disorders. Major players in the biosimilar interleukins market are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech, and Sunshine Guojian Pharmaceutical. The regions covered in the biosimilar interleukins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global biosimilar interleukins market is segmented - 1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6 2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Others 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes

The therapeutic proteins market consists of sales of therapeutic proteins. Therapeutic proteins provide important therapies for diseases such as diabetes, cancer, infectious diseases, hemophilia, and anemia. The global therapeutic proteins market is expected to grow from $90.53 billion in 2020 to $98.1 billion in 2021 at a compound annual growth rate (CAGR) of 8.4%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $155.06 billion in 2025 at a CAGR of 12.1%. Advance technologies for protein-based drug development drives the therapeutic proteins market. Therapeutic proteins cannot be synthesized chemically, they need to be produced by genetic engineering and recombinant DNA technology in living cells or organisms. Protein-engineering platform technologies such as glycoengineering, pegylation, Fc-fusion, albumin fusion, albumin drug conjugation help to increase the production yield, product purity, circulating half-life, targeting, and functionality of therapeutic protein drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, coagulation factor IX recombinant human are some therapeutic protein drugs developed using protein engineering technologies approved by FDA in the past five years. Increasing biosimilar drugs in global market decline the growth of the therapeutic proteins market. Patent expiry of therapeutic proteins such as monoclonal antibodies give space for entry of biosimilar. In EU, AbbVie evidenced patent expiration of Humira (adalimumab) in 2018, five biosimilar of Humira from Mylan, Amgen, Sandoz, Samsung Bioepis received drug approvals from European commission to enter the EU market. These cost-effective treatments similar to original biologics decline the revenue and sales of therapeutic proteins. Monoclonal antibody drug approvals are increasing in the protein therapeutic segment. Chronic diseases such as cancer, immunological disorders are well treated with monoclonal antibodies. Monoclonal antibodies are dominant and well-established product class in the protein therapeutic segment with more safety and immunogenicity than antibodies. Cell-based expression systems such as Chinese hamster ovary (CHO) mammalian cell expression system with latest technologies increased the productivity of monoclonal antibodies by overcoming the problems associated with earlier antibody drugs. In last five years, FDA approved 213 drugs, among them 44 are monoclonal antibodies. In 2018, twelve monoclonal antibodies were approved by FDA for the treatment of cancer and immunological disorders. In the United States, therapeutic protein drug manufacturers file therapeutic biologics application (BLA) to FDA for the product approvals. The drug approved through BLA should be proved as safe, pure and potent. FDA consolidated review of most therapeutic proteins in Center for Drug Evaluation and Research (CDER). In European Union, biologics are regulated by Committee for Medicinal Products for Human Use (CHMP) for marketing authorization. In June 2018, Sanofi, a therapeutic solutions provider acquired Ablynx for $4.8 billion. With this acquisition, Sanofi strengthen its R&D strategy with the addition of Ablynx’s nanobody technology platform. Sanofi will also focus on technologies addressing multiple disease targets with single multi-specific molecules. Ablynx, a biopharmaceutical company based in Ghent, Belgium, that develops proprietary therapeutic proteins based on single-domain antibody fragments. Major players in the market are Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd. The countries covered in the global therapeutic proteins market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global therapeutic proteins market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global therapeutic proteins market is segmented - 1) By Product Type: Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone 2) By Application: Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Others 3) By Function: Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics

The protein inhibitors market consists of sales of protein inhibitors by entities (organizations, sole traders, and partnerships) that are engaged in the manufacturing of protein inhibitors. Protein synthesis inhibitors stop the development of cells by disrupting the process leading to the generation of new proteins. Protein inhibitors is a pharmaceutical drug that acts on the proteins (special target) in the body and finds applications in the treatment of various diseases such as cancer, autoimmune diseases, infectious diseases, and others. The global protein inhibitors market is expected to grow from $56.97 billion in 2020 to $62.54 billion in 2021 at a compound annual growth rate (CAGR) of 9.8%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $88.74 billion in 2025 at a CAGR of 9%. The increasing prevalence of chronic diseases is predicted to contribute to the growth of the protein inhibitors market over the forecast period. Chronic diseases such as cancer, cardiovascular diseases, and autoimmune diseases are becoming more prevalent. According to the World Health Organization, chronic diseases are expected to become the seventh leading cause of death globally by the end of 2030. Moreover, according to the National Health Council’s report published in 2019, there were approximately 133 million Americans affected by chronic diseases, estimated to be 40% of the total population of the country. In the USA, the number is expected to reach 157 million by 2020, with 87 million people having multiple conditions. Protein inhibitors are used for the treatment of these diseases attributing to fewer adverse effects and higher efficacy. Therefore, an increasing number of people with chronic diseases are anticipated to propel the demand for protein inhibitors market. The high cost of protein inhibitors used for cancer is anticipated to limit the growth of the protein inhibitors market in the near future. Monoclonal antibodies are a type of protein made in the laboratory to bind substances in the body including cancer cells and are used to treat various types of cancer. Monoclonal antibodies therapies are considered to be costlier when used for cancer. For instance, according to the National Center for Biotechnology Information, the average price of monoclonal antibody was $96,731 for 34 monoclonal antibodies indication combinations. Oncology and hematology monoclonal antibodies represented 40% of approved monoclonal antibodies indication combinations, yet accounted for more than 85% of those priced $100,000 or higher. The price of oncology or hematology monoclonal antibodies was $149,622 higher than those used in metabolic or cardiovascular disorders, $106,830 higher than in ophthalmology, $128,856 higher than in infectious diseases or allergy, and $98,981 higher than in immunology. Thus, the high cost of protein inhibitors including monoclonal antibodies for the treatment of cancer is expected to hinder the market’s growth. Companies in the protein inhibitors market are increasingly investing in various strategic initiatives such as partnerships and collaborations to develop new drugs to meet the market demand. Strategic collaborations and partnership agreements help companies to expand their existing product portfolio and geographical presence. For instance, in February 2020, Catalent, Inc., a USA-based provider of delivery technologies, drug manufacturing, gene therapies, biologics, and consumer healthcare products announced the partnership agreement with Zumutor Biologics Inc., an immune-oncology company based in the USA to manufacture ZM008, a monoclonal antibody targeting solid tumors. Moreover, in July 2018, Anima Biotech, a USA-based biotechnology company announced a partnership agreement with Eli Lilly and Company, a USA-based pharmaceutical company for the development and discovery of translation inhibitors of several protein targets using Anima Biotech's translation control therapeutics platform. In December 2019, Sanofi S.A. is a France-based pharmaceutical company announced the acquisition of Synthorx, Inc., a biotechnology company for $2.5 billion. The acquisition is aimed at boosting the immune-oncology pipeline of Sanofi S.A. Synthorx, Inc.’s novel discovery platform has developed a molecule with the potential to become a foundation for the next generation of combination therapies for the treatment of cancer. THOR-707 by expanding the number of T-cells and natural killer cells in the body can be combined with other oncology medicines for treating cancer. Synthorx, Inc. is a USA-based company specializing in protein therapeutics for improving and prolonging the lives of people with autoimmune diseases, inflammatory diseases, and cancer. The major players covered in the global protein inhibitors market are Bayer AG, Astra Zeneca, Roche, Teva, Apotex, Novartis, Glaxosmithkline, Pfizer, Boehringer Ingelheim, F. Hoffmann-La Roche, Abbott Laboratories, Amgen Inc., Baxter International Inc., Merck & Co. Inc. The countries covered in the global protein inhibitors market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global protein inhibitors market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global protein inhibitors market is segmented - 1) By Product: Protein Kinase Inhibitors, Monoclonal Antibody, Others 2) By Application: Oncology, Inflammatory Diseases, Others 3) By Distribution Channel: Hospital Pharmacies, Independent Pharmacies, Online Pharmacies

CAR-T Therapy Market Definition

The chimeric antigen receptor -T therapy market consists of sales of CAR-T therapy products and related services by entities (organizations, sole traders and partnerships) that develop chimeric antigen receptor (CAR) T-cell therapies to treat blood cancers. CAR-T therapy is type of immunotherapy in which T-cells taken from patient’s blood are modified in a laboratory with the addition of a special protein receptor that grants T-cells the power to recognize as well as kill cancer cells easily, along with infusing the same back into that patient. This special protein receptor, known as the chimeric antigen receptor (CAR), attaches to a specific protein on a patient’s cancer cells. The infused cells multiply and prevail in the patient’s body as living drugs. This industry includes establishments that are involved in the research and development to introduce new targeted cell therapies for treating indications related mostly to hematological malignancies. However, some of the pipeline CAR-T therapies are aimed at targeting solid tumors including pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain tumor, and other cancer types.